Table 3.
Study | Clear purpose | Patient continuity | Data collection | Appropriate endpoint | Objective evaluation endpoint | Adequate follow-up time | Low lost to follow-up rate | Sample size estimation | Total score |
---|---|---|---|---|---|---|---|---|---|
Cicero et al. 2020 [24] | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 0 | 12 |
Cecchini et al. 2021 [25] | 2 | 2 | 2 | 2 | 1 | 2 | 0 | 0 | 11 |
Sforza et al. 2017 [26] | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 0 | 13 |
Montes et al. 2020 [27] | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 0 | 12 |
Takahashi et al. 2021 [28] | 2 | 2 | 1 | 2 | 1 | 2 | 1 | 0 | 11 |
Kwakman et al. 2018 [29] | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 0 | 13 |
Moehler et al. 2021 [30] | 2 | 2 | 1 | 2 | 1 | 1 | 2 | 0 | 11 |
Yoshida et al. 2020 [31] | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 15 |
Wallander et al. 2020 [32] | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 0 | 13 |
Satake et al. 2020 [33] | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 15 |
Carries et al. 2019 [34] | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 0 | 12 |